Organization Profile

You just read:

Medunik Canada signs an exclusive agreement with HRA pharma for commercialization of Lysodren® (mitotane) in Canada, for the treatment of inoperable adrenal cortical carcinomas

News provided by

Médunik Canada

Jan 16, 2019, 10:00 ET